Genetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in Rhesus Macaques by Varela, M. et al.
  
 
 
 
 
Varela, M., Verschoor, E., Lai, R.P.J., Hughes, J., Mooj, P., McKinley, T., 
Fitzmaurice, T.J., Landskron, L., Willett, B.J., Frost, S.D.W., Bogers, W.M., and 
Heeney, J.L. (2013) Genetic imprint of vaccination on simian/human 
immunodeficiency virus type 1 transmitted viral genomes in Rhesus 
Macaques. PLoS ONE, 8 (8). e70814. ISSN 1932-6203  
 
 
Copyright © 2013 The Authors 
 
 
 
http://eprints.gla.ac.uk/84634 
 
 
 
Deposited on: 22 August 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Genetic Imprint of Vaccination on Simian/Human
Immunodeficiency Virus Type 1 Transmitted Viral
Genomes in Rhesus Macaques
Mariana Varela1*¤a, Ernst Verschoor2, Rachel P. J. Lai1, Joseph Hughes2, Petra Mooj2,
Trevelyan J. McKinley1, Timothy J. Fitzmaurice1¤b, Lisa Landskron1¤c, Brian J. Willett3, Simon D. W. Frost1,
Willy M. Bogers2, Jonathan L. Heeney1
1Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom, 2Department of Virology, BPRC, Rijswijk, The Netherlands, 3MRC-University
of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Glasgow, Scotland
Abstract
Understanding the genetic, antigenic and structural changes that occur during HIV-1 infection in response to pre-existing
immunity will facilitate current efforts to develop an HIV-1 vaccine. Much is known about HIV-1 variation at the population
level but little with regard to specific changes occurring in the envelope glycoprotein within a host in response to immune
pressure elicited by antibodies. The aim of this study was to track and map specific early genetic changes occurring in the
viral envelope gene following vaccination using a highly controlled viral challenge setting in the SHIV macaque model. We
generated 449 full-length env sequences from vaccinees, and 63 from the virus inoculum. Analysis revealed a different
pattern in the distribution and frequency of mutations in the regions of the envelope gene targeted by the vaccine as well
as different patterns of diversification between animals in the naı¨ve control group and vaccinees. Given the high stringency
of the model it is remarkable that we were able to identify genetic changes associated with the vaccination. This work
provides insight into the characterization of breakthrough viral populations in less than fully efficacious vaccines and
illustrates the value of HIV-1 Env SHIV challenge model in macaques to unravel the mechanisms driving HIV-1 envelope
genetic diversity in the presence of vaccine induced-responses.
Citation: Varela M, Verschoor E, Lai RPJ, Hughes J, Mooj P, et al. (2013) Genetic Imprint of Vaccination on Simian/Human Immunodeficiency Virus Type 1
Transmitted Viral Genomes in Rhesus Macaques. PLoS ONE 8(8): e70814. doi:10.1371/journal.pone.0070814
Editor: Welkin E. Johnson, Boston College, United States of America
Received February 14, 2013; Accepted June 24, 2013; Published August 14, 2013
Copyright:  2013 Varela et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Evolutionary analysis was supported by a Wellcome Intermediate Clinical Fellowship while the animal work by National Institutes of Health (NIH) grant
1P01AI06628. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Mariana.varela@glasgow.ac.uk
¤a Current address: MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and
Life Sciences, Glasgow, Scotland
¤b Current address: Department of Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom
¤c Current address: Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
Introduction
The development of a vaccine against human immunodeficiency
virus type 1 (HIV-1) is a global health priority and is currently one of
the greatest scientific challenges given the propensity of this virus to
rapidly evolve within and between hosts. The phase III RV144
clinical trial in Thailand [1] generated a number of interesting leads
regarding the immune correlates of protection, especially with
respect to immune responses focussed on the HIV-1 envelope [2,3].
The most intriguing finding from the RV144 trial is the correlation
of protective efficacy of vaccine antibodies directed at the V1-V2
region of envelope. A major focus of prophylactic HIV-1 vaccines is
the identification of envelope structures capable of inducing broadly
neutralizing antibodies (NAbs). While the passive administration of
neutralizing monoclonal antibodies (MAbs) alone have demonstrat-
ed convincing protection against a variety of viral challenges in pre-
clinical models [4–10], the induction of broadly NAbs by
immunisation with current recombinant forms of the HIV envelope
glycoprotein (Env) remains elusive mainly due to the great variability
of Env. While the discovery of broadly neutralizing MAbs and the
detection of broadly neutralizing polyclonal sera from HIV-1
infected individuals provides evidence that this goal is achievable
[11,12], evidence supporting the role of non-neutralising anti-Env
antibodies in vaccine-induced protection from infection has been
growing.
Antibodies directed against Env have been shown to shape
within-host virus evolution, to induce viral escape mutations [13]
and are associated with slow disease progression in long-term non-
progressors [14]. Only a few studies have taken the painstaking
effort of thoroughly dissecting the immunological pressures and
the molecular events of the autologous neutralising response in a
small population of well-defined individuals infected with related
variants [15–19]. In particular, the definition of epitopes that drive
early neutralizing activity in response to Env vaccination has been
greatly overlooked [20]. This has been deemed critical to the
identification of regions that the virus cannot change without a
great fitness cost considering there is increasing evidence
demonstrating that there are limits to the extent of variation that
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the virus can tolerate [21–23]. This in turn has a direct impact on
the development of novel vaccination strategies and antigens since
traditional vaccination approaches have failed to induce broadly
and potent NAbs against HIV-1. Sieve analysis comparing
breakthrough viral populations between vaccine and placebo
recipients is an important approach for evaluating the impact of
putative immune correlates of protection [17,19]. However, the
complexity of the clinical setting in which the genetic composition
of the viral population to which different individuals are exposed
to, exact time of exposure, the dose, the different routes of
infection and potential secondary exposures are compound
variables that make the analysis of the vaccine immune response
on different viral populations between hosts extremely difficult.
Well-controlled pre-clinical vaccine studies in non-human prima-
tes however provide a unique opportunity to address these issues.
The design of chimeric simian/human immunodeficiency virus
(SHIVs) bearing HIV-1 env genes for pre-clinical vaccine
evaluation allows a direct comparison between changes occurring
in the env gene at the molecular level in a native context in the face
of antibody responses. Despite the drawbacks such as the small
groups of animals and the short duration of viremia with most
virus challenge stocks, the use of HIV-1 env chimeric SIVmac
(SHIV) viruses capable of infecting macaques has proven to be a
strategically important model to assess HIV-1 Env vaccine
candidates for efficacy in vivo prior to large-scale clinical trials.
In this study we aimed at identifying early specific changes
occurring in the HIV-1 env gene under the pressure of pre-existing
vaccine-induced immune responses and evaluate if sieve analysis
could be used as a correlate of protection in SHIV pre-clinical
efficacy studies. To this end, env genes were amplified directly from
plasma using single genome amplification (SGA) from rhesus
macaques that were part of a B-cell based pre-clinical vaccine trial
and were challenged via the intrarectal route with SHIVSF162P4.
Sequences derived from vaccinees and control animals were
analysed and compared to search for signature changes associated
with vaccine-induced antibody responses. This study provides a
unique opportunity to examine the effects of pre-existing
immunity on the evolution of the env gene without additional
vaccine antigens as confounding factors since only Env-based
antigens were used for immunization.
Materials and Methods
Ethics statement
The study involved a retrospective analysis of samples from an
immunogenicity trial involving 20 adult rhesus macaques,
weighing between 4 and 9 kg body and housed at the Biomedical
Primate Research Centre (BPRC), The Netherlands. The trial
included challenge with SHIVSF162P4. The trial protocol was
approved (permit number DEC#515) by the Committee of the
Ethics of Animal Experiments of Biomedical Primate Research
Centre, Animal Welfare Assurance Number VVP/V 9513. The
qualification of the members of this committee including their
independence from a research institute is requested in the Wet op
de Dierproeven (1996). The project was monitored by a qualified
independent veterinarian, specially regarding the ethical issues of
the project.
The use of non-human primates in The Netherlands is legalized
based on the law: ‘‘Wet op de Dierproeven’’ and adaptations as
published in the Staatscourant (48 (1975); 336 (1985); 585 (1992);
435 (1993); 806 (1994); 137(1996); 138(1996); 139 (1996); 5 (1997)
and the EU guidelines 86/609/EEG. These laws guarantee the
qualification of researchers, veterinary staff and animal caretakers
involved in experimental studies and breeding of non-human
primates. All animals were either from the breeding stock of the
BPRC or purchased from breeding centers in Asia. Identification
of imported macaques was confirmed by CITES. The accommo-
dation of laboratory animals was in accordance with animal
welfare requirements (1993); Wet op de dierproeven (WOD 1996);
Gezondheids-en welzijnswet (GWWD 1996). The animal facilities
were licensed to perform studies with genetically modified
organisms up to DM3 level (Law on Genetically Modified
Organisms, GMO law nr 108, 1996).
All steps were taken to ameliorate the welfare and to avoid the
suffering of the animals. At the start of the trial, all animals were in
good health and met with the following criteria: no previous
immunosuppresive treatment; negative for simian T-lymphotropic
virus, simian retrovirus and simian immunodeficiency virus (SIV);
low or no IFN-c, IL2 or IL4 responses against HIV Env, Gag, Pol
or Nef antigens. They were housed in adjoining, single primate
cages, because of the risk of cross-infection following challenge
with SHIV. Animals could interact socially with their neighbors
and had auditory and visual contact with others in the same room.
Enrichment was provided in the form of pieces of wood, mirrors,
food puzzles, variety of food and other home made or
commercially available enrichment products. The facility was
under controlled conditions of humidity (60%), temperature (23–
25uC) and lighting (12 hour light/dark cycles). Animals were fed
with standard food pellets, fruit and bread. Water was provided ad
libitum. Animals were sedated with ketamin before blood was taken
and challenge performed. The number of monkeys to be used in
the trial was reduced to a minimum by statistical power
calculations and variance values from previous studies to calculate
the minimal group sizes to give statistical significance. All the
included in this study were humanely euthanized at the end of the
study, which was considered the human endpoint. Before
euthanasia animals were sedated with ketamine and then received
a lethal intravenous injection of pentobarbital.
At the BPRC all animal handling is performed in the
Department of Animal Science (ASD) according to the laws as
described above. At the BPRC a large experienced staff is
available including full time veterinarians and pathologists. The
ASD is regularly inspected by the responsible authorities (VWA)
and an independent Animal Welfare Officer.
All animals were Mamu A*001, B*008 and B*017 negative
except BB204 (A*001 postive), R01070, R00042, BB204, 98041,
96050 (B*008 positive) and R01012 (B*017 positive).
Study design
Twenty Indian rhesus macaques (Macaca mulatta) were random-
ized into four groups of five and included in the study. Animals
were primed at week 0 and boosted at weeks 6 and 16 as follows:
Group 1 (gp140 glycoproteins): three injections with recombinant
o-gp140 from HIV-1 Q461 (subtype A), HIV-1 SF162 (subtype B)
and HIV-1 TV1 (subtype C); Group 2: week 0, one injection with
HIV-1 SF162 V2 peptide, HIV-1 SF162 V3 cyclised peptide and
CD4 binding site mimotope; week 6 same as week 0 with the
addition of the gp140 glycoproteins used in Group 1; and week 16
gp140 proteins alone; Group 3: week 0 one injection with a
membrane proximal external region peptide, a second CD4
binding site mimotope (different from the one administered to
Group 2) and a HIV-1 TV1 V3 cyclised peptide; week 6, the same
immunogens plus the same gp140 glycoproteins used in Group 1;
and only the gp140 glycoproteins at week 16. Group 4: three
injections with adjuvant alone. All animals were challenged intra-
rectally at week 24 with 1,800 TCID50 of the cell-free challenge
stock SHIVSF162P4 [24,25].
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Figure 1. Trial outcome. A) Schematic representation of the experimental design. B) Infection kinetics after mucosal challenge with
SHIVSF162P4. Viral loads were measured at the indicated times post infection for a period of 12 weeks in each of the experimental groups. Since the
detection level of the assay was 100 viral copies/ml negative samples were assigned a value of 2 (Log10 of 100). C) Distribution of peak viral RNA
loads. Continuous lines indicate the means of each group; upper discontinuous line indicates viremia 1 log lower than the mean peak viremia of
control animals while lower line indicates the limit of detection of the assay (100 viral RNA copies). Control animal 96015 was not included in the
graphic and calculations since its viral load continue to increase during the study period.
doi:10.1371/journal.pone.0070814.g001
Figure 2. Binding antibodies after the last immunization. The presence of binding antibodies against gp140 or the indicated peptides used
for immunization was measured using ELISA at a single serum dilution. The sera collected after 2 weeks of the last immunization was analysed
against gp140 while the sera collected 6 weeks the last immunization was analysed against the indicated peptides. The interrupted lines depict the
threshold OD value above which a sample is considered positive (3 times the OD value of the pre-immunization sera).
doi:10.1371/journal.pone.0070814.g002
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Immunogens
Gp140 glycoproteins (50 mg), cyclised V3 peptides (250 mg) or
linear peptides (250 mg) conjugated to keyhole limpet haemocy-
anin (180 mg) were formulated in MF59 adjuvant plus CpG. o-
gp140s have five amino acid mutations in the SU-TM cleavage
site. Proteins were purified from CHO supernatant using a
combination of GNA, DEAE and CHAP columns. At the final
stage, trimers are separated from the monomers using gel filtration
column. The sequences of the synthetic peptides used were the
following: HIV-1 SF162 V3 CTRPNNNTRKSITIGPGRA-
FYATGDIIGDIRQAHC; HIV-1 TV1 V3
CTRPNNNTRKSVRIGPGQAFYATNDVIGNIRQAHC;
HIV-1 SF162 V2 IRNKMQKEYALFYKL; HIV-1 TV1 V2
LRDKKHKEYALFYKL; mimotope to monoclonal IgG1 b12:
NWPRWWEEFVDKHSS [26] (Group 2); mimotope to mono-
clonal IgG1 b12: HERSYMFSDLENRC [27] (Group 3); Mem-
brane proximal region NEQEL LELDK WASLWN [28]. A C-
terminal cysteine was added to all peptides for conjugation to
keyhole limpet haemocyanin.
Viral load determination
Plasma virus load was determined by a quantitative competitive
reverse transcription-PCR as previously described [29].
Neutralization assays
Neutralizing titers of sera were assessed using single-round
competent viruses bearing an Env protein of the SHIVsf162p4 virus
inoculum or specific Env identified by the evolutionary analysis
and TZM-bl cells as a target as previously described [30]. Briefly,
virus was incubated with serially diluted antisera for 1 hour at
37uC before being added to wells of 96-well microplates seeded
with TZM-bl cells. After 48 hours cells were lysed and luciferase
signal in the lysate was developed with Britelite Plus substrate
(Perkin Elmer) and read on a VICTOR Light luminometer
(Perkin Elmer).
ELISAs
Binding antibodies were determined in plasma or serum by
ELISA. In brief, ELISA plates were coated with the indicated
antigens and plates were blocked with PBS containing 0.1%
Tween20, 4% BSA and 1% newborn calf serum. Subsequently,
plates were incubated with EDTA plasma or serum samples
diluted in blocking buffer. After washing in a PBS/0.1% Tween20
buffer the wells were incubated with an alkaline phosphatase (AP)-
conjugated goat anti-human IgG antibody (1:1000, Sigma). pNPP
substrate (Sigma) in Tris buffer was used for colour development.
The reaction was stopped by the addition of H2SO4 and colour
intensity was measured on a BIORAD microplate reader at
405 nm (Biorad, model 680).
ELISpots
The quantification of antigen-specific cytokine-secreting cells
was performed as previously described by Koopman et al. [31].
The various antigens were used to measure antigen-specific
immune responses, medium alone was used as negative control,
whilst phorbol myristate acetate (PMA) (20 ng/ml) plus ionomycin
(1 mg/ml) stimulation was used as positive control. In brief,
46106 cells/ml were stimulated for 24 hours. For the enumera-
tion of antigen specific cytokine production, non-adherent cells
were collected and plated at 26105 cells/well in triplicate in a 96-
well ELISpot plate with the same antigen again. The microtiter
plates were pre-coated with MAbs specific for the lymphokines
anti-IFN-c MAb (MD-1, U-Cytech, Utrecth, The Netherlands),
anti-IL-4 MAb (QS-4, U-Cytech) and anti-IL-2 MAb (B-G5,
Diaclone Laboratories, Besanc¸on Cedex, France). Detection of the
cytokine secreting cells took place after 15 hours for IL-4 and 4
hours for IFN-c as well as IL-2. The cells were lysed and the debris
was washed away before adding detector antibodies. IFN-c, IL-2
and IL-4 were detected using biotinylated rabbit-anti-rhesus
macaque IL-2, biotinylated rabbit-anti-rhesus macaque IFN-c,
or biotinylated mouse-anti-rhesus macaque IL4 (U-Cytech). Spots
were visualized using streptavidin-HRP and an AEC (3-amino-9-
ethylcarbazole) colour development system. Two background
responses (medium only) were subtracted.
Viral RNA extraction and cDNA synthesis
Viral RNAs were extracted from 200 ml using a QIAamp viral
RNA kit (Qiagen) following the manufacturer’s instructions. Viral
RNA was reverse-transcribed using Superscript III (Invitrogen) as
previously described [32].
Single genome amplification
Nested PCRs were performed using a cDNA dilution that
yielded less than 30% positive reactions in a 96 well plate at which
the majority of positive reactions would result from the amplifi-
cation of one single copy of cDNA. PCRs and nested PCRs were
performed using Platinum Taq DNA Polymerase High FidelityH
Table 1. Pre-challenge neutralizing antibody responses.
Pre-
immune Week 14 Week 22 Week 24 Week 36
Group 1
R01090 ,20 33 2018 909 18498
R00040 ,20 ,20 1345 474 3538
R01089 ,20 39 5001 1624 6687
R01093 ,20 ,20 3775 752 24800
R99008 ,20 ,20 891 485 7830
Group 2
R01012 ,20 ,20 550 360 .87480
8813 ,20 ,20 969 602 160
R01070 ,20 ,20 566 441 2762
8865 ,20 ,20 1896 669 272
R99037 ,20 ,20 116 24 785
Group 3
R00042 ,20 ,20 860 511 .15884
R00057 ,20 ,20 1081 952 .15887
BB204 ,20 ,20 781 800 16998
98041 ,20 ,20 855 474 81
8758 ,20 ,20 433 261 7063
Group 4
R99006 ,20 ,20 ,20 ,20 3680
96050 ,20 ,20 ,20 ,20 19781
R00056 ,20 ,20 ,20 ,20 41620
R99004 ,20 ,20 ,20 ,20 42643
96015 ,20 ,20 ,20 ,20 ,20
Sera collected at different time points before and after challenge were tested
against single-round competent virus bearing an Env protein of the SHIVsf162p4
virus inoculum. The reciprocal of serum dilutions at which 50% inhibition of
viral infection (IC50) occurred are reported.
doi:10.1371/journal.pone.0070814.t001
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(Invitrogen) following manufacture’s instructions. BFwout
59GCAATAGTTGTGTGGTCCATAGTAATCATAG39 and
SHIVR2 59GCCTCACTGATACCCCTACC39 primers were
used for first round PCRs and BFW162-AC AATAGACCGGT-
TAATCGATAGAATAACAG and SHIVp4RW 59TCCTCTA-
GACCCTGATTGTATTTCTGTCC39 primers were used for
second round PCRs. 5 ml of the PCR product was treated with
ExoSap-ITH(USB) diluted and sequenced directly using an
Applied Biosystems 3730 DNA Analyzer. Partially overlapping
primers were used and both DNA strands were sequenced.
Amplification from a single template was verified by the inspection
of individual chromatograms and sequences with mixed based
were excluded from the analysis.
Samples from animals R01093 week two, R00057 week four
and BB204 week 4 post-challenge were subjected to bulked PCR
following the same protocol and conditions as for the SGA
samples. These three PCR products were then cloned using
TOPO XL PCR cloning kit (Invitrogen) following manufacture’s
instructions except that MAX EfficiencyH Stbl2 (Invitrogen)
chemically competent cells were used for transformation. Individ-
Figure 3. T-cell ELISpot responses 2 weeks after the last immunization. Positive IFN-c, IL-2 and IL-4 ELISPots per million cells are shown for
each animal after stimulation with full-length recombinant proteins of clades A, B and C and V2-V3 peptides of clades B and C once 2 background
responses were subtracted. Positive responses are defined as responses above 50 spot forming units per million cells.
doi:10.1371/journal.pone.0070814.g003
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ual bacterial clones were picked up, grown for 24 hours at 30uC
when plasmid DNA was extracted. Sequencing was performed as
described above.
Evolutionary analysis
Individual env sequence reads were assembled using the
Lasergene SeqMan (DNASTAR) package. Sequences were
manually aligned using Se-Alv2.0a11 Carbon (http://tree.bio.ed.
ac.uk/software/seal/). Protein sequence alignments were per-
formed using MAFFT-6.859 (http://mafft.cbrc.jp/alignment/
software/). All sequences were tested for hypermutation by
APOBEC3G/F with Hypermut 2.0 (www.hiv.lanl.gov). Recom-
bination was screened by the Genetic Algorithms for Recombi-
nation Detection (GARD) [33] available in the Datamonkey web
interface of the HyPhy software package using the TrN93
nucleotide substitution bias model and beta-gamma site-to-site
variation (2 rate classes).
Maximum likelihood (ML) trees were estimated using PhyMl
3.0 [34] and RAxML 7.2.8 [35,36] using the generalized time
reversible substitution model. Sequence diversity was estimated
using MEGA 5 [37] after the removal of hypermutated sequences.
The mean protein sequence divergence from a reference (vaccine
sequence) was estimated using DIVEIN based on phylogenetic
trees rather than pairwise comparisons [38] and differences among
groups were compared using ANOVA followed by Tukey’s to
identify groups. Mean number of non-synonymus (dN) and
synonymus (dS) substitutions per site (ratio dN/dS) were estimated
using the Single Likelihood Ancestor Counting (SLAC) algorithm
available in the Datamonkey web interface of the HyPhy software
package [39] using alignments stripped of hypermutated sequenc-
es. To address the number of potential N- linked glycosylation sites
nucleotide sequences were translated into amino acid sequences
using Se-Alv2.0a11 Carbon and then were screened by N-
GlycoSite [40]. Shannon entropy was calculated using Entropy-2
(www.hiv.lanl.gov).
All statistical calculations were carried out using R 2.14.1 [41]
or GraphPad Prism.
Accession numbers
All sequences were deposited in GenBank (accession numbers
JX191370 to JX191881).
Online supplemental material
A summary of the sequences analysed is shown in Table S1.
Figure 4. A) Maximum likelihood phylogenetic tree of the envelope gene of the virus inoculum. The scale bar represents one nucleotide
substitution. B) Frequency of each inoculum variant at the amino acid level. The number of each viral genome present within the inoculum
was estimated based on the amino acid sequence (black bars) and at the nucleotide level (grey bars).
doi:10.1371/journal.pone.0070814.g004
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Figure 5. Composite phylogenetic tree of all envelope sequences along with sequences of the challenge inoculum. Master phylogeny
shows no clustering according to vaccination status. Insert shows representative intrahost phylogenies. Animal-derived sequences are color-coded.
Black circles indicate inoculum-derived sequences. The scale bar indicates one nucleotide substitution.
doi:10.1371/journal.pone.0070814.g005
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Results
Vaccine trial outcome
The development of an HIV-1 vaccine has been elusive. While
impressive protection from SHIV challenge has been achieved by
passive immunisation with neutralising monoclonal antibodies in
vivo, recapitulation of these impressive results by active vaccination
has not been achieved with current trimeric forms of the HIV-1
envelope. One likely explanation is that the polyclonal antibody
response to the global gp140 immunogen insufficiently amplifies
antibodies to the relatively few but important neutralising epitopes
clustered at certain sites of the structure. Thus, we designed a
study in which animals would first be immunised with peptides
corresponding to neutralising epitopes (ie, MPER, V3, V2, CB4bs)
to prime a B-cell response to these epitopes, and then amplify
those by boosting with a conformationally correct gp140 (gp140
trimer). To this end, twenty Indian rhesus macaques were divided
into three groups of five animals (groups 1 to 3) that were
immunized and one group of five (group 4) that was used as an
adjuvant alone control. Immunized animals received a combina-
tion of gp140 envelope proteins from subtypes A, B and C and
peptides corresponding to V2, V3, CD4 binding site and
membrane proximal external region (MPER) as described in
methods and shown in Figure 1A. Eight weeks after the last
immunization all animals were exposed to a single dose of 1,800
TCID50 of SHIVSF162P4 virus stock via the intrarectal route [42].
As a measure of protection, viral loads were monitored from the
day of challenge and at regular intervals up to twelve weeks post-
challenge (Figure 1B). We evaluated protection from infection by
comparing: i) viral loads at week 2 post challenge; ii) the 8-week
area under the curve; and iii) peak viral loads. For viral loads at
week 2, we found statistically significant differences between
groups, in particular between control animals and animals from
group 1 (Kruskal-Wallis test, p,0.05; Dunn’s multiple comparison
test, group 1 vs group 4: p,0.05). For the 8-week area under the
curve, we found statistically significant differences between groups,
in particular between control animals and animals from group 2
(Kruskal-Wallis test, p,0.05; Dunn’s multiple comparison test,
group 2 vs group 4: p,0.05). For peak viral loads, we did not find
statistically significant differences between controls and vaccinees,
however a delay in peak viral loads was detected in some animals
belonging to group 1.
Moreover, we found that 4 out of 5 animals of group 1 had peak
viral loads that were at least one log lower than the mean peak
viral load of control animals. Indeed, one of these animals had just
a transient detectable sample and remained aviremic during the
length of the study. Interestingly 2 animals of group 2 were
aviremic throughout the study while another animal had a
detectable transient viremia at week 2 post-challenge, although the
later was positive for the MHC class I allele Mamu B*008, which
is associated with control of SIVmac239 infection. Finally, 3
animals of group 3 had peak viral loads that were at least one log
lower than the mean peak viral load of control animals.
In summary, if we consider a reduction in viral load of at least
one log with respect to control animals a measure of partial viral
containment as previously utilized by others [43,44], then 2
animals were completely protected from infection, another 2 had
transient infections and a further 7 animals were partially
protected by this vaccine strategy, providing a combined 66%
complete and partial protection (Figure 1C).
Pre-challenge immune responses
Antibody (Ab) titers were monitored along the course of
immunization. All vaccinated animals developed Env-specific Abs
against the three subtypes after the third immunization as
determined by ELISA using recombinant gp140 (Figure 2). In
addition, animals from groups 2 and 3 that were primed with
peptides against V2, V3 and MPER developed binding antibodies
against those regions (Figure 2). In some cases, animals from group 1
also developed antibodies against those regions. Most importantly,
all animals belonging to the vaccinated groups developed NAbs
against SHIVSF162P4 measured by the TZM-bl assay before
challenge while no neutralizing activity was detected in the serum
of control animals (Table 1). In general, we found that the animals
that had the highest peak viral loads were the ones that had the
lowest NAb titres, a trend that was confirmed for all the vaccinated
groups, although this correlation only reach statistical significance
for animals of group 2 (Pearson correlation coefficient, -.088;
P,0.05).
The presence of cellular immune responses was evaluated by
quantification of antigen-specific cytokine-secreting cells (IFN-c,
IL-2 and IL-4) by enzyme-linked immunospots (ELISpot) on fresh
PBMC isolated 2 weeks after the last immunization (Figure 3).
Most of vaccinees had IFN-c-secreting cells after stimulation with
recombinant proteins of HIV clades A, B and C while no
responses were detected in naı¨ve control animals. We found no
correlation between peak viral loads and the development of
cellular responses.
Vaccination does not constrain the transmission
bottleneck
To characterize the impact that pre-existing immunity had on the
breakthrough viral population, full-length env sequences were
derived from plasma samples taken 2 and 4 weeks post-challenge
from 6 vaccinees and 2 control animals. As this was a retrospective
study only of subset of unbiased samples were available for sequence
analysis and unfortunately no samples were available from animals
belonging to Group 2. However, we included sequences of two
animals (Ri102 and Ri112) as extra controls that were part of a
previous study [32] and that were challenged with the same
inoculum and route and had comparable viral loads and kinetics of
infection to the contemporary controls. 512 sequences, including 63
sequences from the virus inoculum, were obtained using SGA
followed by direct sequencing (19 to 60 per animal; median 46)
(table S1). This virus inoculum has been previously characterized
Table 2. Number of founder viral variants.
Group 1 Group 3 Group 4 (controls)
R00040 R01093 R99008 R00057 BB204 8758 R00056 R99004 Ri102 Ri112
Number of
founder
viruses
4 5 3 6 3 11 6 6 6 7
doi:10.1371/journal.pone.0070814.t002
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[32], however additional genomes were included for this analysis.
The phylogenetic relationships among sequences were estimated
using maximum likelihood (Figure 4A). The inoculum was
characterized by the lack of a majority variant. In fact, only 8 out
of the 63 inoculum variants were present at a number higher than
one. Randomly distributed and shared polymorphisms were
identified. When nucleotide sequences were translated to amino
acids, 38 unique phenotypes were identified. The number of each of
these unique phenotypes is shown in Figure 4B.
To estimate the number of viral genomes (founder viruses) that
established infection upon challenge the phylogenies of each
intrahost data set were reconstructed using maximum likelihood
(not shown). Multiple transmission events/founder viruses were
identified when lineages shared 2 or more mutations as defined by
Keele et al. [45]. A phylogeny reconstructed using all the available
sequences (Figure 5), including sequences from the virus inoculum,
revealed no particular clustering according to vaccination status.
Multiple viruses established infection in all of the animals, which
was revealed by the complex interspersed sequences across the
tree. This is in agreement with our previous study where the same
virus inoculum, infection route and dose were used [32]. The total
number of transmissions (founder viruses) for each animal is shown
in Table 2. We found no statistically significant differences in the
number of transmissions/founder viruses between controls and
vaccinated animals, which is not surprising considering that: 1) the
use of such a high inoculum dose made this a very stringent
challenge model; and 2) the immunization protocol had little
clinical benefit in terms of protection from infection.
Global filter analysis
Firstly, we estimated the mean protein sequence divergence
from the vaccine inserts and compared it among groups (ANOVA
followed by Tukey’s test as a post hoc test). We found a statistically
significant difference between controls and vaccinees in the V1/
V2 region when the divergence was calculated against clade A and
B vaccine inserts (Figure 6A, top panels). For the V3 region we
found statistically significant differences in divergence against the 3
clade vaccine inserts between vaccinees and controls (Figure 6A,
middle panel). When the divergence was estimated and compared
for the MPER we only found statistically significant differences
from the clade A gp140 vaccine insert (Figure 6A, bottom panel).
In the majority of the cases where we found significant differences
between controls and vaccinees, the divergence was higher in
vaccinees. When the divergence from the peptides used for
priming group 3 was compared among groups (Figure 6B) we
found that it was higher in groups 1 and 3 compared to control
although this difference did not reach statistical significance. The
divergence from the CD4 binding site mimotope was not
calculated because this peptide was shown not to be immunogenic
[46]. On the other hand, we observed that the divergence from the
consensus sequence of the inoculum was greater in controls than in
vaccinees (t-test p,0.01) (Figure 6B, right panel). In fact, we
cloned 8 envs derived from the inoculum and 5 envs derived from
animals (founder envs) and tested their sensitivity to neutralization
against the day of challenge sera from animals that were
considered protected (R8813, R8865, R01089 and R01070)
versus the sera of protected and non-protected animals (R8813,
Figure 6. Protein divergence between animal sequences and vaccine inserts. The mean protein divergence from the protein sequences
included in the vaccine regime (gp140 in A and peptides used in boosting in B) and standard deviation are reported. Only statistically significant
comparisons are indicated. C) The reciprocal of serum dilutions at which 50% inhibition of viral infection (IC50) occurred from sera derived from the
day of challenge from animals that were protected (left) or protected and non-protected (right) against pseudotypes harbouring Envs derived from
the virus inoculum or animal plasma (founder Envs) were compared. No statistically significant differences were identified (un-paired t-test).
doi:10.1371/journal.pone.0070814.g006
Figure 7. Differences in Shannon entropy between controls
and vaccinees. The Shannon entropy was calculated at each
nucleotide position for pooled vaccinees, group 1 vaccinees and group
3 vaccinees and subtracted from the entropy calculated for control
animals. Sites displaying a statistically significant difference in entropy
between controls and vaccinees are indicated in red.
doi:10.1371/journal.pone.0070814.g007
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R8865, R01089, R01070, R00040, R01093, R99008, R00057,
BB204 and 8758) and we found no differences in neutralization
which indicates that Envs in the inoculum and founder Envs are
similar in terms of neutralization sensitivity (Figure 6C).
We found that vaccinated animals had a higher proportion of
sequences harbouring deletions (vaccinated median = 0.2 versus
control media = 0.055; Wilcoxon test, p,0.05), indicating that
there was a higher tendency for the generation of aberrant genomes
in vaccinated animals. Most of the deletions were not in-frame and
there were no compensatory mutations to maintain an open reading
frame. Six genomes had large deletions of more than 100 amino
acids in-frame, which likely give rise to non-functional proteins.
We did not find changes in the number or distribution of
predicted sites for N-linked glycosylation between vaccinated and
control animals suggesting that if NAbs impose pressure to drive
early diversification events this does not occur primarily by
changing glycosylation sites. This is in agreement with the findings
of Wood et al. in acute subtype B infections in humans [47].
Local filter analysis
We next sought to identify nucleotide sites that showed a
significant difference in variability between controls and vaccinees.
To this end the Shannon entropy was estimated at each nucleotide
position and was compared between vaccinees and controls using a
Monte Carlo randomization strategy implemented in Entropy-2.
We identified a total of 74 nucleotide sites where there was a
statistical significant difference in the Shannon entropy between
control animals and vaccinees (Table 3 and Figure 7). In 25 of these
sites the Shannon entropy and thus diversity was higher in vaccinees
while in 49 sites the diversity was higher in control animals indicating
that vaccinees were constrained in the number of sites in which
diversification could occur (Fisher exact test P,0.05). The
differences in Shannon entropy between controls and vaccinees
seemed to occur in clusters, where several sites in close proximity
displayed higher entropy for either controls or vaccinees and not as
isolated single sites probably due to genetic linkage. In particular, we
identified two major regions in which the Shannon entropy was
higher in vaccinees: from amino acids 87 to 96 (HXB2 88 to 97) in
C1 and from amino acids 140 to 150 (HXB2 141–152) in V1. In
control animals the Shannon entropy was higher in two other
regions: from amino acids 422 to 435 (HXB2 429–442) in C4 and
482 to 486 (HXB2 488–492) in C5. This suggests that different
regions of the envelope underwent different patterns of diversifica-
tion in vaccinees and control animals.
Intriguingly, despite the presence of binding antibodies against
V3 in both groups 1 and 3, as measured by ELISA (Figure 2),
there were no sites showing significant differences in entropy
between controls and vaccinees in this region. In contrast to the
differences in Shannon entropy between controls and vaccinees
that seemed to occur in clusters in gp120, all the sites identified in
gp41 appeared isolated. Interestingly most of the identified sites
were located in the cytoplasmic tail. This together with the
identification of sites in the signal peptide suggest that the level of
expression and incorporation of the envelope might be important
to sustain viral replication in the presence of antibody pressure.
Identification of nucleotide sites-of-interest
A usual concern that arises when performing the type of analysis
described above is the identification of nucleotide sites that are not
the result of simply random de novo mutation events occurring
during viral replication or in vitro amplification. Thus, to identify
nucleotide sites that showed strong evidence of change in the
distribution of bases relative to the inoculum, we applied a
Bayesian technique that has been used successfully for similar
HIV-1 and flu intra-host data sets before [32,48,49]. A total of 21
nucleotide sites were recognized using this approach of which 11
were non-synonymous mutations (Table 3). Six sites were present
in more than one animal, which could be indicative of sites that
are important for transmission or early replication events. A single
site (nucleotide 1314; HXB2 1334) showed evidence of change in
the distribution of bases from the inoculum only in vaccinees,
which could be indicative of mutations generated as a consequence
of vaccination. All the sequences from animals R01093 and BB204
harboured a thymine at that position while a mixed population of
thymine and cytosine was present in the inoculum. Since at least
one of the inoculum genomes transmitted to these animals
harboured a thymine at this position the most likely scenario is
that this mutation was transmitted rather than generated de novo in
independent animals as a result of vaccination. However, it is
striking that in these 2 animals the entire viral population
harboured a thymine at week 2 post-challenge and this residue
persisted in the entire viral population at week 4 post-challenge.
Importantly the majority of the sites displaying a statistically
significant difference in Shannon entropy between vaccinees and
controls were also confirmed independently using the Bayesian
model, thus the differential diversity observed at those positions
was not the result of purely random events but very likely it was a
predisposed outcome of the immunization protocol.
Finally, we estimated the selection pressures acting upon the env
gene by calculating the global dN/dS ratio. The global dN/dS ratio
for the complete data set was 0.56 consistent with the envelope gene
being under purifying selection. We identified 2 codons under
positive selection (164 and 829) and 8 codons under negative
selection (46, 131, 251, 253, 438, 486, 588, 697) most of which were
identified in a previous study where animals were challenged with
the same inoculum [32]. We found no differences in the global dN/dS
between controls and vaccinees (0.53 and 0.62 respectively).
Discussion
NAbs have been shown to shape the intra-host evolution of the
HIV-1 envelope [50–57] but little is known regarding their impact
on early diversification events of breakthrough viral variants upon
transmission. The analysis of the HIV-1 viral founding population
of individuals enrolled in the STEP trial revealed that even
thought the immunization regime had no clinical efficacy, CTL
responses left a genetic imprint in the viral regions targeted by the
vaccine [17]. Most importantly, analysis of the breakthrough viral
population of the RV144 trial found 2 signature sites associated
with vaccine-induced immune responses [19]. Similarly, studies
performed in rhesus macaques infected with SIV showed that
different mutational patterns developed in animals subject to
immunization regimes in comparison with control animals
[15,16]. Here, we presented data showing that pre-existing
envelope only targeted immunity left an imprint, although modest,
in the early viral population evidenced by the fact that viruses
infecting immunized animals harboured genomes that encoded
envelopes that differed more from the vaccine inserts than non-
immunized controls. This is to our knowledge the first experi-
mental study showing the impact of immune responses on viral
genomes leading to infection in a highly controlled setting
provided by: 1) rhesus macaques infected with chimeric SIV/
HIV virus as a challenge where the HIV-1 Env glycoprotein can
be studied in an animal model and the time of infection is known
as well as the viral population to which animals are exposed to;
and 2) the use of Env-based antigens in isolation without any other
confounding factors (antigens).
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We first quantified the viral founder variants and we observed
that vaccination did not affect the transmission bottleneck. This is
not surprising since a single high dose challenge was used which
lead to the transmission of multiple viral variants in all the animals.
Although a lower number of genomes seemed to have been
transmitted to animals of group 1 (median of 4 against a median of
6 in controls), this difference did not reach statistical significance
probably due to the low number of animals available for
retrospective analysis. Unfortunately no samples were available
from animals belonging to group 2 that had a better vaccine-
induced protection.
Global measures of intrahost variation such as mean pairwise
distance, proportion of phylogenetic informative mutations or
measures of evolutionary forces acting upon env failed to identify
differences between vaccinated and control animals, which would
suggest that this vaccination protocol did not affect the mutational
dynamics of env. However, we found that env underwent different
patters of diversification in controls and vaccinees: we found that
although viruses infecting vaccinees were in general constrained to
diversify away from the consensus sequence of the inoculum they
tended to encode for Env proteins that in specific regions differed
from the vaccine inserts, corresponding with the presence of
binding antibodies towards those regions. Importantly, several
sites-of-interest were also identified in the same regions. However,
given the limitation on animal numbers inherent to non-human
primate studies, these results should be interpreted with caution
and within the context of this particular immunization protocol.
Similar to the scenarios proposed by Rolland et al. [17] for
CTL-based vaccines in the presence of pre-existing immune
responses generated through Env-based vaccination strategies,
incoming viruses could take two different but not mutually
exclusive routes upon transmission: i) viruses that are similar to the
vaccine are filtered out by either neutralization or other antibody-
mediated effector functions; or ii) viruses are forced to diversify
away from the vaccine. The fact that we found no clustering of env
sequences according to vaccination status and that the divergence
in some of the regions of the viral envs encoded by vaccinees was
higher in vaccinees than in controls point to the diversification
away of the founder viruses from the vaccine ‘‘strain’’ as the
mechanism ruling genetic variation in this animal model. We
acknowledge that due to our acute post-infection period in which
samples were available for sequence analysis (2 and 4 weeks post-
challenge) it is not possible for a mutation that confers higher
fitness to arise and replace the whole viral population [45]. Thus
we attribute to this the cause of why the differences in divergence
from the vaccine inserts between vaccinees and controls were
modest and in some comparisons, they did not reach statistical
significance. If we had used a more neutralisation resistant SHIV
strain (which are inherently more pathogenic), we may have
overwhelmed the modest vaccine effect completely and possibly
have lost this observation. The analysis of later samples would
have been beneficial but these were unfortunately not available.
On the other hand the use of neutralisation sensitive SHIV model
has the limitation of short periods of viremia, which only allows the
study of early diversification events since all animals will rapidly
clear the infection.
The poor clinical efficacy of this trial could be attributed in part
to the stringent challenge protocol that the animals were subjected
to: a single high intrarectal dose. Here we showed that all the
animals were infected by multiple viral variants, a scenario that is
unlikely to reflect natural HIV-1 infection. It could be argued that
a better outcome could have been obtained if animals were
infected with a single viral genome. We have previously shown
that in terms of transmitted genotypes, a single challenge with an
intermediate challenge dose better mimics the early diversification
events seen in natural HIV-1 infection [32]. It would then seem
sensible to re-evaluate the non-human primate challenge models
to avoid ‘‘missing’’ potential vaccine candidates. Importantly, in
light of recent findings, sieve analysis should now be considered
critical part of the evaluation of immune correlates of protection
and taken into account when powering pre-clinical vaccine trials
in non-human primates.
In conclusion, we showed that an immunization protocol based
only on Env antigens left an impact, although modest, on the viral
population detected early in infection despite having little clinical
efficacy. This is surprising considering the relatively small number of
animals involved in the trial and the high stringency of the challenge
protocol. Our results indicate that the analysis of the early viral
population should be a critical component of the evaluation of
efficacy of pre-clinical vaccine trials in non-human primates.
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